RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Portland, ME · Scarborough, ME · South Portland, ME · +172 more sites